Genelux (GNLX) Amortization of Deferred Charges (2025 - 2026)
Genelux's (GNLX) quarterly Amortization of Deferred Charges came in at $89000.0 in Q1 2026, up 11.25% year-on-year from $80000.0 in Q1 2025, and up 11.25% quarter-over-quarter from $80000.0 in Q1 2025.
Genelux (GNLX) Amortization of Deferred Charges (2025 - 2026) Analysis & Trends
Genelux's Amortization of Deferred Charges history runs 2 years deep, the most recent figure standing at $89000.0 for Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Nanobiotix | 1,785.11 Bn | 1,785.05 Bn | - |
| 2 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - |
| 3 | BeOne Medicines | 473.57 Bn | 468.78 Bn | 1.35 Bn |
| 4 | Vertex Pharmaceuticals | 123.78 Bn | 116.54 Bn | 2.59 Bn |
| 5 | Regeneron Pharmaceuticals | 71.73 Bn | 62.98 Bn | 3.31 Bn |
| 6 | Belite Bio | 62.12 Bn | 62.12 Bn | - |
| 7 | Argenx Se | 54.64 Bn | 49.45 Bn | 1.41 Bn |
| 8 | Alnylam Pharmaceuticals | 38.05 Bn | 35.05 Bn | 959.66 Mn |
| 9 | Revolution Medicines | 36.28 Bn | 36.28 Bn | - |
| 10 | Genelux | 128.04 Mn | 128.04 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 89,000.00 |
| Mar 31, 2026 | 89,000.00 |
| Mar 31, 2025 | 80,000.00 |
| Mar 31, 2025 | 80,000.00 |